Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479876 | 0.98 | NPC1 (0.42) | NPC1RAB9ATP53THRBBCHE | |
| SCHEMBL4329036 | 0.87 | NPC1 (0.43) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL4330936 | 0.87 | PSEN1 (0.45) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL5491712 | 0.87 | NPC1 (0.41) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL5483579 | 0.85 | NPC1 (0.41) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL4337898 | 0.84 | NPC1 (0.41) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL5478173 | 0.84 | PSEN1 (0.39) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL4327916 | 0.82 | KCNH2 (0.47) | NPC1RAB9ATP53BCHEMAPT | |
| SCHEMBL5478271 | 0.81 | GRM5 (0.52) | NPC1RAB9ATP53THRBMAPT | |
| SCHEMBL1544442 | 0.80 | KCNH2 (0.47) | NPC1RAB9ATP53BCHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7576077-B2 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716152-A2 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | disclosed |
| WO-2005080397-A2 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | NPC1 2565/4885RAB9A 929/4885TP53 4725/4885 |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM5 | NPC1 2379/4885RAB9A 1393/4885TP53 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.